Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns

– First neonate subject with X-linked hypohidrotic ectodermal dysplasia completes dosing with the novel ectodysplasin replacement protein EDI200 – Cambridge, Mass. – Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy...

Source: http://blogohj.oralhealthjournal.com/clinical/edimer-initiates-phase-2-trial-of-edi200-in-xlhed-affected-male-newborns

dental extractions implant dentures gum surgery maxillofacial jaw surgery wisdom tooth removal cost